Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors

NCT04976218 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04976218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04976218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
March 15, 2022
Completion date
December 31, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr overexpression, solid tumor, adult